BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

DBT is supporting 210 R&D projects worth Rs 174 Cr in nanomedicine: Dr Jitendra Singh

28 September 2026 | News

India has established a regulatory framework for nanopharmaceuticals through guidelines jointly developed by the DBT, ICMR, and CDSCO



Addressing the inaugural ceremony of the World Congress on Nanomedicine 2026 at Vigyan Bhawan in New Delhi, Dr Jitendra Singh, Minister of State (Independent Charge) for Science & Technology, said that nanomedicine will drive the next generation of preventive medicine and personalised healthcare.

The World Congress on Nanomedicine 2026, being held from Sept 27 to 30, organised by the Institute of Nano Medical Sciences, Faculty of Medical Sciences, University of Delhi, attracted over 2,000 participants. These include eminent scientists and young researchers who are discussing emerging advances and applications in the field of nanomedicine.

Detailing the government's support for nanomedicine research, Dr Jitendra Singh said that the Department of Biotechnology (DBT) is providing financial assistance of Rs 174 crore to 210 research and development (R&D) projects in the field of nanomedicine. These projects include targeted drug delivery, cancer nanomedicine, nanomedicine for infectious diseases, nucleic acid and vaccine delivery, nanodiagnostics and imaging, regenerative medicine and wound healing, as well as nanotoxicology and regulatory science.

Among promising research areas, the Minister mentioned precision nano-injections and targeted breast cancer nanomedicines, in addition to oral insulin nanoparticles and nanobots for breast cancer. He recalled that earlier attempts at oral insulin had encountered challenges related to absorption and digestive enzymes. He said that advances in nanotechnology could offer new possibilities to address these challenges.

He said that India has established a regulatory framework for nanopharmaceuticals through guidelines jointly developed by the DBT, ICMR, and CDSCO. This framework provides the basis for evaluating the safety , quality, and efficacy of nanopharmaceutical products.